精神分裂症多基因风险评分可预测首发精神病抗精神病药疗效
该研究在四个独立首发精神病队列(总N=510)中检验精神分裂症多基因风险评分(PRS)是否预测抗精神病药疗效。结果显示,较高PRS显著预测12周随访时症状评分更高,合并部分r=0.18,解释3.24%方差;低PRS患者更可能治疗应答(OR=1.91)。PRS负担可能作为预后生物标志物。
要点
- 较高精神分裂症PRS预测首发精神病患者抗精神病药治疗后症状改善更少。
- PRS对12周调整后症状评分有显著预测作用(合并部分r=0.18,解释3.24%方差)。
- 低PRS患者比高PRS患者更可能治疗应答(两个白人样本OR=1.91)。
核心结论
- 精神分裂症PRS较高的首发精神病患者抗精神病药治疗后改善倾向更小。
- PRS负担可能作为抗精神病药疗效的预后生物标志物。
研究设计与样本
- 研究纳入四个独立首发精神病队列,总样本N=510,均接受抗精神病药初始治疗。
- 所有受试者经标准SNP阵列基因分型并插补至1000 Genomes Project参考面板。
- PRS基于精神分裂症大规模GWAS(Psychiatric Genomics Consortium)结果计算。
- 症状采用总症状评定量表在基线和第12周或脱落前末次随访时测量。
主要发现
- 在发现队列中,较高PRS显著预测12周随访时更高症状评分(控制基线症状、性别、年龄和 ethnicity)。
- PRS阈值设为p<0.01在发现队列中结果最强,并用于其他三个队列的重复验证。
- 合并重复分析中,较高PRS显著预测更严重的治疗后症状,并在三个重复队列中的两个单独显著。
- 四个队列合并,PRS显著预测调整后12周症状评分(合并部分r=0.18;解释3.24%方差)。
- 低PRS患者比高PRS患者更可能治疗应答(两个白人样本OR=1.91)。
关键数值与推荐
- PRS阈值设为p<0.01在发现队列中给出最强结果,并用于重复验证。
- 合并部分r=0.18,解释3.24%方差,对应12周调整后症状评分。
- 两个白人样本中,低PRS患者治疗应答的OR=1.91。
临床怎么用
- PRS可能辅助识别抗精神病药治疗应答可能较差的首发精神病患者。
- 较高PRS提示需更密切监测症状改善和考虑个体化治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Pharmacogenomic studies of antipsychotics have typically examined effects of individual polymorphisms. By contrast, polygenic risk scores (PRSs) derived from genome-wide association studies (GWAS) can quantify the influence of thousands of common alleles of small effect in a single measure. The authors examined whether PRSs for schizophrenia were predictive of antipsychotic efficacy in four independent cohorts of patients with first-episode psychosis (total N=510). METHOD: All study subjects received initial treatment with antipsychotic medication for first-episode psychosis, and all were genotyped on standard single-nucleotide polymorphism (SNP) arrays imputed to the 1000 Genomes Project reference panel. PRS was computed based on the results of the large-scale schizophrenia GWAS reported by the Psychiatric Genomics Consortium. Symptoms were measured by using total symptom rating scales at baseline and at week 12 or at the last follow-up visit before dropout. RESULTS: In the discovery cohort, higher PRS significantly predicted higher symptom scores at the 12-week follow-up (controlling for baseline symptoms, sex, age, and ethnicity). The PRS threshold set at a p value <0.01 gave the strongest result in the discovery cohort and was used to replicate the findings in the other three cohorts. Higher PRS significantly predicted greater posttreatment symptoms in the combined replication analysis and was individually significant in two of the three replication cohorts. Across the four cohorts, PRS was significantly predictive of adjusted 12-week symptom scores (pooled partial r=0.18; 3.24% of variance explained). Patients with low PRS were more likely to be treatment responders than patients with high PRS (odds ratio=1.91 in the two Caucasian samples). CONCLUSIONS: Patients with higher PRS for schizophrenia tended to have less improvement with antipsychotic drug treatment. PRS burden may have potential utility as a prognostic biomarker.
引用
- Zhang JP, Robinson D, Yu J, et al. Schizophrenia Polygenic Risk Score as a Predictor of Antipsychotic Efficacy in First-Episode Psychosis. Am J Psychiatry. 2018. PMID: 30392411. doi:10.1176/appi.ajp.2018.17121363
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。